BioCentury

8:00 AM GMT, Mar 25, 2002
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Alkermes buys into specialty pharma

Alkermes Inc.'s acquisition of Reliant Pharmaceuticals LLC checks two boxes in ALKS's bid to become a big cap specialty pharmaceutical company. The deal puts ALKS within spitting distance of the top tier of biotech companies valued above $3 billion, and, perhaps more importantly, provides the company with the marketing infrastructure to compete for in-licensing drugs.

"There's a major shift to size and scale in this transaction," said CEO Richard Pops. "We go from being one

Read the full 745 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.